内分泌自身抗体决定免疫检查点抑制剂诱导的内分泌疾病:一项前瞻性研究
该前瞻性研究纳入60例接受免疫检查点抑制剂(ICI)治疗的晚期或转移性实体瘤成人患者,在治疗前及治疗后8-9周和36周检测甲状腺、肾上腺和胰腺抗体及激素水平。14例(23.3%)发生内分泌相关不良事件(ERAE),中位发生时间为首次ICI给药后52天,抗体存在与ERAE显著相关(R2 59.3%,P < 0.001),ERAE与更有利的总生存期相关(P = 0.001)。
要点
- 60例接受ICI治疗的患者中14例(23.3%)发生ERAE,中位发生时间52天。
- 甲状腺功能减退12例(20%),垂体炎2例(3.33%),未观察到糖尿病和原发性肾上腺功能不全。
- 内分泌特异性自身抗体与ERAE显著相关(R2 59.3%,P < 0.001),ERAE与更有利的总生存期相关(P = 0.001)。
核心结论
- 内分泌特异性自身抗体在ERAE发病机制中起重要作用,可能作为预测标志物用于ICI诱导的内分泌疾病的早期识别和治疗。
研究设计与样本
- 前瞻性研究,纳入60例年龄≥18岁、因晚期或转移性实体瘤接受ICI治疗且无已知活动性或既往内分泌疾病的成人患者。
- 在ICI治疗前及治疗后8至9周和36周评估甲状腺、肾上腺和胰腺抗体及激素水平,分析其与ERAE、激素水平变化及总生存期(OS)的关系。
主要发现
- 60例患者中14例(23.3%)检测到ERAE,中位发生时间为首次ICI给药后52天(IQR 38.5-71.5)。
- 甲状腺功能减退发生于12例(20%)患者,2例(3.33%)患者发生垂体炎,未观察到糖尿病和原发性肾上腺功能不全。
- 14例患者检测到抗体(11例基线时存在,3例随访期间出现),抗体存在与ERAE显著相关(R2 59.3%,P < 0.001)。
- 最常见的抗体为甲状腺过氧化物酶抗体(20%)和甲状腺刺激免疫球蛋白(3.3%),1例患者存在抗GAD抗体。
- ERAE的存在与更有利的OS相关(P = 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Incidence and awareness of endocrine-related adverse events (ERAE) associated with use of immune checkpoint inhibitors (ICI) has grown with increased ICI use, yet mechanisms for ERAE prediction, surveillance, and development are not well established. OBJECTIVE: We prospectively evaluated the impact of endocrine autoimmunity on ERAE development and overall survival (OS). METHODS: Adults ≥ 18 years of age prescribed ICI treatment for advanced or metastatic solid tumors and no known active/past endocrine disorders were eligible for enrollment. Thyroid, adrenal, and pancreatic antibodies as well as hormone levels were assessed prior to ICI treatment and at 8 to 9 weeks and 36 weeks after treatment for ERAE in relation to presence and changes in endocrine-specific antibodies, hormone levels, and OS. RESULTS: Sixty patients were enrolled and ERAE were detected in 14 (23.3%), with a median onset of 52 days (IQR, 38.5-71.5) after first ICI dose. Hypothyroidism occurred in 12 (20%) patients, and 2 (3.33%) patients developed hypophysitis. Diabetes and primary adrenal insufficiency were not observed. Antibodies were detected in 14 patients (11 at baseline, 3 developed during follow-up) and their presence was significantly associated with ERAE (R2 59.3%, P < 0.001). Thyroid peroxidase antibody (20%) and thyroid-stimulating immunoglobulin (3.3%) were most common, and anti-GAD was present in 1 patient. The presence of ERAE was associated with a more favorable OS (P = 0.001). CONCLUSION: Endocrine-specific autoantibodies play an important role in ERAE pathogenesis and may serve as predictive markers for early identification and treatment of ICI-induced endocrinopathies.
引用
- Labadzhyan A, Wentzel K, Hamid O, et al. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study. J Clin Endocrinol Metab. 2022. PMID: 35303106. doi:10.1210/clinem/dgac161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。